Elite in Epithelioid Sarcoma

Silvia Stacchiotti

Milan, IT 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Epithelioid Sarcoma
Milan, IT 
OverviewLocationsClinical Research

Overview

Silvia Stacchiotti practices in Milan, Italy. Ms. Stacchiotti is rated as an Elite expert by MediFind in the treatment of Epithelioid Sarcoma. Her top areas of expertise are Solitary Fibrous Tumor, Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, Hemangioendothelioma, and Synovectomy.

Her clinical research consists of co-authoring 263 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 5 articles in the study of Epithelioid Sarcoma.

Gender
Female

Locations

Milan, Italy
Other Locations
Orbassano, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Enrollment Status: Recruiting
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: INBRX-109
Study Phase: Phase 2
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug
Study Drugs: Letetresgene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 2
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Nirogacestat Oral Tablet
Study Phase: Phase 3
Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients
Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients
Enrollment Status: Completed
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Trabectedin, Adriamycin, Dacarbazine
Study Phase: Phase 2
Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
Enrollment Status: Completed
Publish Date: December 04, 2024
Intervention Type: Drug
Study Drugs: Trabectedin, Olaparib
Study Phase: Phase 2
ERibulin in Advanced Solitary Fibrous Tumor, an ItaliaN Sarcoma Group Phase II Study (ERASING)
ERibulin in Advanced Solitary Fibrous Tumor, an ItaliaN Sarcoma Group Phase II Study (ERASING)
Enrollment Status: Completed
Publish Date: September 20, 2024
Intervention Type: Drug
Study Drug: Eribulin
Study Phase: Phase 2
Phase II Study on TSR-042 in Advanced Clear Cell Sarcoma
Phase II Study on TSR-042 in Advanced Clear Cell Sarcoma
Enrollment Status: Terminated
Publish Date: February 01, 2024
Intervention Type: Drug
Study Drug: TSR-042
Study Phase: Phase 2
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2024
Intervention Type: Drug
Study Drugs: Anlotinib, Decarbazine
Study Phase: Phase 3
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: November 08, 2021
Intervention Type: Drug
Study Phase: Phase 1
Phase II Study on Axitinib in Advanced VEGFR and/or PDGFR Solitary Fibrous Tumor
Phase II Study on Axitinib in Advanced VEGFR and/or PDGFR Solitary Fibrous Tumor
Enrollment Status: Completed
Publish Date: September 28, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1b Study of Olaratumab, Doxorubicin and Ifosfamide in the Treatment of Patients With Advanced or Metastatic Soft Tissue Sarcoma
A Phase 1b Study of Olaratumab, Doxorubicin and Ifosfamide in the Treatment of Patients With Advanced or Metastatic Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: September 10, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

263 Total Publications

Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review.
Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review.
Journal: JAMA oncology
Published: October 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Stacchiotti's expertise for a condition
ConditionClose
View All 14 Elite Conditions
View All 8 Advanced Conditions
View All 17 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile